ABSTRACT
This study was carried out to report the experiment with tadenan [a plant extract of Pygeum africanum] in the treatment of men with symptomatic benign prostatic hyperplasia [BPH]. 100 patients with symptomatic BPH were enrolled into this study. In a double-blind prospective randomized manner, the patients were divided into 2 equal groups receiving either Tadenan 25 mg or an identical-looking placebo. The patients were asked to take 2 capsules at morning and evening for 8 weeks. The patients were assessed by calculation of symptom score, physical examination, uroflowmetry tests, measurement of post-voiding residual urine and transrectal ultrasonography. These studies were performed before treatment, at the end of the 8-week course of treatment and 8 weeks after treatment. If compared with pretreatment values, patients of both Tadenan and placebo groups showed a significant improvement in the total Boyarsky score, a significant increase in the peak flow rate, and a significant reduction in the post voiding residual urine. However, the changes in all of these parameters were comparable in patients of both groups at the end of the treatment and 8 weeks after treatment. The prostatic weight showed no change after treatment in both groups